Inimex Pharmaceuticals (Canada) a clinical-stage biopharmaceutical company focused on infectious diseases and inflammatory disorders, closed a $22M Series B financing. Participants include Morningside, Roche Venture Fund, Astellas Venture Management, Advantage Life Science Fund, BC Advantage Funds, BDC Venture Capital, British Columbia Discovery Fund, Canadian Medical Discovery Fund, and Working Opportunity Fund.